Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

LESSONS LEARNED. Pharmacokinetic results underscore that the vorolanib (X‐82) study design was successful without the need for further dose escalation beyond 400 mg once daily (q.d.). Therefore, the recommended dose of X‐82 as a single agent in patients with advanced cancer is 400 mg q.d. BACKGROUND...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2018
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459237/
https://ncbi.nlm.nih.gov/pubmed/30478190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0740
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller